Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novavax’s COVID-19 Shot Finally Authorized In US, But Could Miss Out Again On Bivalent Booster

Still Hoping To Hit $4bn Revenues Despite Slow Start

Executive Summary

A protein-based vaccine for COVID-19 reaches the US at last, but Novavax looks set miss out once again as the fall deadline for BA.4/5 variant-targeting vaccines approaches.

You may also be interested in...



Serum Scores A Double - HPV Vaccine In India, Novavax Vaccine In US

Serum Institute will supply initial doses of NVX-CoV2373 in the US, but late approvals have meant Novavax's vaccine is facing weak demand and surplus stocks in other parts of the world. Meanwhile, Serum has also secured a nod in India for the first indigenously-developed HPV vaccine, also the fifth globally.

Coronavirus Update: FDA Tries To Control J&J’s Vaccine, Extended Use Of Paxlovid

The FDA has also moved to limit use of J&J’s COVID-19 vaccine amid reports of rare but dangerous blood clots, while Regeneron highlighted efforts to get approval for REGEN-COV in its Q1 earnings.

Novavax’s Latecomer COVID-19 Vaccine Impresses With 90% Efficacy Result

Arriving two to three months later than planned, Novavax’s nanoparticle-based vaccine is still a welcome addition to the field, for both rich and poor countries.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146723

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel